Next Article in Journal
Human Autopsy-Derived Scalp Fibroblast Biobanking for Age-Related Neurodegenerative Disease Research
Next Article in Special Issue
Insight into the Role of Angiopoietins in Ageing-Associated Diseases
Previous Article in Journal
A Novel FRET Approach Quantifies the Interaction Strength of Peroxisomal Targeting Signals and Their Receptor in Living Cells
Previous Article in Special Issue
Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab
Review

The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma

1
Department of Internal Medicine and Pediatrics, Department of Gastroenterology and Hepatology, Hepatology Research Unit, Ghent University, B-9000 Ghent, Belgium
2
Department of Basic and Applied Medical Sciences, Gut-Liver Immunopharmacology Unit, Ghent University, B-9000 Ghent, Belgium
*
Author to whom correspondence should be addressed.
Cells 2020, 9(11), 2382; https://doi.org/10.3390/cells9112382
Received: 1 October 2020 / Revised: 23 October 2020 / Accepted: 27 October 2020 / Published: 30 October 2020
(This article belongs to the Special Issue Angiopoietin Signaling)
Due to the usually late diagnosis and lack of effective therapies, hepatocellular carcinoma (HCC), which poses a growing global health problem, is characterized by a poor prognosis. Angiogenesis plays an important role in HCC progression, and vascular endothelial growth factor (VEGF) and angiopoietins (Angs) are key drivers of HCC angiogenesis. VEGF-targeting strategies already represent an important component of today’s systemic treatment landscape of HCC, whereas targeting the Ang/Tie2 signaling pathway may harbor future potential in this context due to reported beneficial anticancer effects when targeting this pathway. In addition, a better understanding of the relation between Angs and HCC angiogenesis and progression may reveal their potential as predictive factors for post-treatment disease progression and prognosis. In this review, we give a comprehensive overview of the complex role of Ang/Tie2 signaling in HCC, pinpointing its potential value as biomarker and target for HCC treatments, aiding HCC diagnosis and therapy. View Full-Text
Keywords: angiopoietin-1; angiopoietin-2; hepatocellular carcinoma; angiogenesis; vascular endothelial growth factor; treatment; biomarker; diagnosis; prognosis angiopoietin-1; angiopoietin-2; hepatocellular carcinoma; angiogenesis; vascular endothelial growth factor; treatment; biomarker; diagnosis; prognosis
Show Figures

Figure 1

MDPI and ACS Style

Vanderborght, B.; Lefere, S.; Vlierberghe, H.V.; Devisscher, L. The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma. Cells 2020, 9, 2382. https://doi.org/10.3390/cells9112382

AMA Style

Vanderborght B, Lefere S, Vlierberghe HV, Devisscher L. The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma. Cells. 2020; 9(11):2382. https://doi.org/10.3390/cells9112382

Chicago/Turabian Style

Vanderborght, Bart, Sander Lefere, Hans V. Vlierberghe, and Lindsey Devisscher. 2020. "The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma" Cells 9, no. 11: 2382. https://doi.org/10.3390/cells9112382

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop